Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (473)	12/9/2002 2:53:00 PM
From: JMarcus	Respond to of 7424

AVGN is giving up last week's gains today. After getting some weekend hype out of Barron's (http://biz.yahoo.com/rc/021208/health_avigen_pickup_1.html) the company's press release summarizing today's news out of ASH is being perceived as underwhelming. biz.yahoo.com I think the following comment from the Yahoo! thread gives a pretty good analysis of the stock situation: <<I do not believe the response is due to technical factors. And I believe the "case by case" presentation is not as professional or scientific as it could be - instead it smacks of anecdote. So what do we have now? 6 subjects, 4 presumably with no response, but probably at low doses, 1 with some response but "mild" side effects leading to discontinuation, 6 weeks of "response" in one patient, and an intimation that hepatic delivery (ouch!) would give better results. Sorry, but with all the cash put in here, this is interesting early information at best, and not much to hype. With only a 6 week window and tiny N, no controls, I'm not sure you can even say how much human proof of concept for a maketable product is seen here, though this is interesting science to be sure. That is why IMHO the price hasn't responded.>> Marc